In a Golden Age of Cancer Care, PBMs Are Holding Us Back We must stop predatory and destructive behaviors Aug 05, 2023
AI-Backed Mammography Keeps Up With Docs for Cancer Detection But can AI capture relevant biological features of detected lesions? Aug 01, 2023
Multi-Cancer Early Detection: 20th-Century Fiction Becomes Reality These tests could soon become a valuable addition to current cancer screening tools Aug 01, 2023
PPIs Linked to Worse Outcomes With Widely Used Breast Cancer Drug Concomitant use of proton pump inhibitors with palbociclib associated with shorter survival Jul 21, 2023
New CMS Coding Shortchanges Natural-Tissue Breast Reconstruction Elisabeth Potter, MD, on the negative effect on women with breast cancer and their surgeons Jul 11, 2023 video
PET-CT Superior to Conventional Scans for Spotting Distant Breast Cancer Mets Study shows twice as many locally advanced patients upstaged with PET-CT vs conventional staging Jun 26, 2023
Breast Cancer Recurrence Risk Varies by Molecular Subtype Korean study suggests need for individualized surveillance, optimized use of breast MRI Jun 21, 2023
Breast Cancer Drugs May Weaken Effects of Weight-Loss Drugs Survivors on aromatase inhibitors lost significantly less weight Jun 18, 2023
Early Invasive Breast Cancer Now Leaves Mostly Long-Term Survivors Mortality risk has decreased substantially since the 1990s Jun 15, 2023
Breast Ultrasound Recs May Not Be Targeting the Right Women It's not just dense breasts that matter, researchers say Jun 12, 2023
How Vax Skeptics Sow Doubt; Gun Death Every 11 Minutes; 90210 Star's Cancer Spreads Health news and commentary from around the Web gathered by Â鶹´«Ã½ staff Jun 08, 2023
Studies Question Role of CDK4/6 Inhibitors in First-Line Advanced Breast Cancer No PFS, OS benefit with first-line versus second-line CDK4/6 inhibition, more toxicity, cost Jun 07, 2023
How a Medical Recoding May Limit Cancer Patients’ Options for Breast Reconstruction Many believe this would restrict women's options for surgery Jun 04, 2023
Chemo-Free Approach Works in Subset of Patients With HER2+ Early Breast Cancer Impressive 3-year invasive DFS seen with adaptive response strategy using FDG-PET Jun 03, 2023
CDK4/6 Extends Reach Into Early-Stage Breast Cancer Addition of ribociclib to endocrine therapy boosts disease-free survival in high-risk disease Jun 02, 2023
ASCO Backs Routine ESR1 Testing for Certain Breast Cancers Activity of elacestrant in EMERALD trial "provides strong signal" for guideline update May 18, 2023
Proposed Breast Cancer Screening Guidelines Are Good, but Not Enough Specifics for older women, Black women, and those with dense breasts are needed May 09, 2023
Thriving After Cancer Tara Sanft, MD, on how clinicians can support patients through difficult times May 02, 2023 podcast
Many With Cancer Predisposition Diseases Unaware of Genetic Status Moreover, a significant proportion do not qualify for genetic screening under current guidelines Apr 19, 2023
Taxane, Anthracycline Combo Most Effective in Reducing Breast Cancer Recurrence Chemotherapy regimens with higher cumulative dose provide greatest benefit Apr 14, 2023
Local Anesthesia Before Breast Cancer Surgery Improves OS in Randomized Trial Intervention is inexpensive, easy to implement, researchers say Apr 07, 2023
High Out-of-Pocket Costs Tied to Less Follow-Up After Initial Mammography Plans dominated by copays and deductibles are associated with higher out-of-pocket costs Mar 27, 2023
Progestin-Only Birth Control Linked to Small Increase in Breast Cancer Risk But risk is similar to combined hormonal contraceptive use Mar 22, 2023
Focus on Optimizing Use of CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer Choice of agent, post-progression treatment, and resistance mechanisms top unanswered questions Mar 08, 2023
Understanding of HER2-Low Breast Cancer Continues to Evolve New breast cancer subtype proves challenging to define molecularly, pathologically, clinically Mar 07, 2023
Cases of Breast Implant-Associated Lymphoma Continue to Accumulate More than 1,300 cases and 35 deaths, as reports of other implant-linked malignancies emerge Mar 06, 2023
'Our Goal Is Not to Omit Radiation Therapy' in Breast Cancer Honing indications for de-escalation of treatment intensity and, yes, selective omission of RT Mar 06, 2023
Antibody-Drug Conjugates Take Breast Cancer Field by Storm Established role in metastatic disease, may eventually replace chemotherapy Mar 04, 2023
These Surgeries Made the Sharpest Turns to Outpatient Setting After COVID Several procedures saw significant increases in outpatient volumes Mar 03, 2023
How to Make Meaningful Moves Toward Health Equity in Cancer Care Addressing the three R's: resources, research, and racism Feb 27, 2023
Safe to Omit RT After Lumpectomy in Certain Older Breast Cancer Patients Radiotherapy reduced local recurrence, but showed no effect on OS, distant recurrence Feb 15, 2023
FDA Greenlights First Drug for ESR1-Mutated Breast Cancer Elacestrant almost doubled PFS versus standard endocrine therapy in advanced ER+/HER2- disease Jan 30, 2023
MRI-Guided Focused Ultrasound Eases Pain From Bone Metastases More responses with ultrasound, but quality-of-life scores lower vs EBRT in nonrandomized trial Jan 11, 2023
Genomic Assay May Pinpoint Who Can Skip RT After Breast-Conserving Surgery Patients categorized as low risk with 16-gene signature showed no significant benefit with RT Jan 06, 2023
Optimizing Treatment for Older Patients With HR+ Low-Risk Breast Cancer Five days of radiotherapy, five years of hormonal therapy, or somewhere in between? Jan 05, 2023
Mixed Results With Hormonal Strategies for Premenopausal Breast Cancer Exemestane reduced recurrence, metastasis versus tamoxifen, but no survival benefit Dec 20, 2022
Less Is More Wins Again: Avoiding Node Dissection in Early Breast Cancer First comparison of targeted sentinel node assessment shows no difference in recurrence rates Dec 09, 2022
Adding AKT Inhibitor Doubles PFS in Advanced, HR-Positive Breast Cancer In phase III trial, capivasertib benefited patients with or without AKT pathway alterations Dec 09, 2022
Oral SERD Tops Fulvestrant for PFS in ER-Positive Breast Cancer Camizestrant also led to meaningful PFS improvements in those with detectable ESR1 mutations Dec 09, 2022
Continuing CDK4/6 Inhibitor Beyond Progression No Help in Metastatic Breast Cancer Prior therapy, baseline mutations confound results; "intriguing" benefit with PD-L1 inhibitor Dec 09, 2022
